Cargando…

Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients

Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients. Methods: We collected clinicopathological data on bladder cancer pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Abudurexiti, Mierxiati, Ma, Jie, Li, Yao, Hu, Chuanyi, Cai, Zhikang, Wang, Zhong, Jiang, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870851/
https://www.ncbi.nlm.nih.gov/pubmed/35200552
http://dx.doi.org/10.3390/curroncol29020052
_version_ 1784656856082284544
author Abudurexiti, Mierxiati
Ma, Jie
Li, Yao
Hu, Chuanyi
Cai, Zhikang
Wang, Zhong
Jiang, Ning
author_facet Abudurexiti, Mierxiati
Ma, Jie
Li, Yao
Hu, Chuanyi
Cai, Zhikang
Wang, Zhong
Jiang, Ning
author_sort Abudurexiti, Mierxiati
collection PubMed
description Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients. Methods: We collected clinicopathological data on bladder cancer patients ≤40 years old diagnosed between 1975 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database. Survival curves were generated using the Kaplan–Meier method, and the differences between groups were analyzed using the log-rank test. Univariate and multivariate Cox hazards regression analyses were performed to define hazard ratios (HRs) for cancer-specific survival (CSS). Results: There were statistical differences in race, histological type, cancer stage, tumor size, and surgery treatment groups between overall survival and CSS. Only tumor size and cancer stage were significant independent prognostic risk factors in younger bladder cancer patients for the prediction of CSS. Conclusion: Tumors greater than 30 mm in size and a more advanced stage of bladder cancer were indicative of a poor prognosis in bladder cancer patients ≤40 years old, and long-term follow-up is suggested.
format Online
Article
Text
id pubmed-8870851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88708512022-02-25 Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients Abudurexiti, Mierxiati Ma, Jie Li, Yao Hu, Chuanyi Cai, Zhikang Wang, Zhong Jiang, Ning Curr Oncol Article Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients. Methods: We collected clinicopathological data on bladder cancer patients ≤40 years old diagnosed between 1975 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database. Survival curves were generated using the Kaplan–Meier method, and the differences between groups were analyzed using the log-rank test. Univariate and multivariate Cox hazards regression analyses were performed to define hazard ratios (HRs) for cancer-specific survival (CSS). Results: There were statistical differences in race, histological type, cancer stage, tumor size, and surgery treatment groups between overall survival and CSS. Only tumor size and cancer stage were significant independent prognostic risk factors in younger bladder cancer patients for the prediction of CSS. Conclusion: Tumors greater than 30 mm in size and a more advanced stage of bladder cancer were indicative of a poor prognosis in bladder cancer patients ≤40 years old, and long-term follow-up is suggested. MDPI 2022-01-28 /pmc/articles/PMC8870851/ /pubmed/35200552 http://dx.doi.org/10.3390/curroncol29020052 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abudurexiti, Mierxiati
Ma, Jie
Li, Yao
Hu, Chuanyi
Cai, Zhikang
Wang, Zhong
Jiang, Ning
Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients
title Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients
title_full Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients
title_fullStr Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients
title_full_unstemmed Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients
title_short Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients
title_sort clinical outcomes and prognosis analysis of younger bladder cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870851/
https://www.ncbi.nlm.nih.gov/pubmed/35200552
http://dx.doi.org/10.3390/curroncol29020052
work_keys_str_mv AT abudurexitimierxiati clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients
AT majie clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients
AT liyao clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients
AT huchuanyi clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients
AT caizhikang clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients
AT wangzhong clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients
AT jiangning clinicaloutcomesandprognosisanalysisofyoungerbladdercancerpatients